Type I interferons in anticancer immunity (Q38509280)

3 September 2017

1 reference

title

Type I interferons in anticancer immunity (English)

1 reference

3 September 2017

1

Laurence Zitvogel

0 references

Guido Kroemer

5

Guido Kroemer

0 references

Lorenzo Galluzzi

2

Lorenzo Galluzzi

0 references

Oliver Kepp

3

Oliver Kepp

0 references

Mark J. Smyth

Mark J Smyth

4

0 references

publication date

1 June 2015

1 reference

Nature Reviews Immunology

3 September 2017

published in

1 reference

3 September 2017

volume

15

1 reference

3 September 2017

issue

7

1 reference

3 September 2017

page(s)

405-414

1 reference

Virus interference. I. The interferon

3 September 2017

cites work

1 reference

Type I interferon: friend or foe?

31 March 2020

1 reference

IFN-β-specific signaling via a unique IFNAR1 interaction

31 March 2020

1 reference

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

31 March 2020

1 reference

Direct effects of type I interferons on cells of the immune system

31 March 2020

1 reference

Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1

31 March 2020

1 reference

Type I interferons in infectious disease

31 March 2020

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

The three Es of cancer immunoediting

31 March 2020

1 reference

A critical function for type I interferons in cancer immunoediting

31 March 2020

1 reference

Adaptive immunity maintains occult cancer in an equilibrium state

31 March 2020

1 reference

Critical role for constitutive type I interferon signaling in the prevention of cellular transformation.

31 March 2020

1 reference

Viruses and interferon: a fight for supremacy

31 March 2020

1 reference

Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration.

31 March 2020

1 reference

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα( ) tumorigenesis

31 March 2020

1 reference

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

31 March 2020

1 reference

Type I IFN contributes to NK cell homeostasis, activation, and antitumor function

31 March 2020

1 reference

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

31 March 2020

1 reference

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

31 March 2020

1 reference

Identification of a dendritic cell receptor that couples sensing of necrosis to immunity

31 March 2020

1 reference

The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice

31 March 2020

1 reference

Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses

31 March 2020

1 reference

STING is a direct innate immune sensor of cyclic di-GMP

31 March 2020

1 reference

Innate and adaptive immune cells in the tumor microenvironment

31 March 2020

1 reference

Innate immune sensing of cancer: clues from an identified role for type I IFNs

31 March 2020

1 reference

Production of type I interferons: plasmacytoid dendritic cells and beyond

31 March 2020

1 reference

Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation

31 March 2020

1 reference

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

31 March 2020

1 reference

Interferons and their stimulated genes in the tumor microenvironment

31 March 2020

1 reference

Impaired IFN- Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

31 March 2020

1 reference

An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival

31 March 2020

1 reference

Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis

31 March 2020

1 reference

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

31 March 2020

1 reference

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

31 March 2020

1 reference

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

31 March 2020

1 reference

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

31 March 2020

1 reference

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

31 March 2020

1 reference

Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy.

31 March 2020

1 reference

The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy

31 March 2020

1 reference

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis

31 March 2020

1 reference

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity

31 March 2020

1 reference

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

31 March 2020

1 reference

Type I-IFNs control GVHD and GVL responses after transplantation

31 March 2020

1 reference

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

31 March 2020

1 reference

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

31 March 2020

1 reference

Trial Watch: Lenalidomide-based immunochemotherapy

31 March 2020

1 reference

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

31 March 2020

1 reference

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

31 March 2020

1 reference

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

31 March 2020

1 reference

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

31 March 2020

1 reference

Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.

31 March 2020

1 reference

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

31 March 2020

1 reference

Trial watch: Immunostimulatory cytokines in cancer therapy

31 March 2020

1 reference

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

31 March 2020

1 reference

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

31 March 2020

1 reference

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

31 March 2020

1 reference

Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma

31 March 2020

1 reference

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

31 March 2020

1 reference

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

31 March 2020

1 reference

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

31 March 2020

1 reference

Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia

31 March 2020

1 reference

Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor

31 March 2020

1 reference

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

31 March 2020

1 reference

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

31 March 2020

1 reference

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera

31 March 2020

1 reference

Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.

31 March 2020

1 reference

Interferon α may be back on track to treat acute myeloid leukemia

31 March 2020

1 reference

Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).

31 March 2020

1 reference

Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa

31 March 2020

1 reference

Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre

31 March 2020

1 reference

How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).

31 March 2020

1 reference

How I treat polycythemia vera

31 March 2020

1 reference

Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study

31 March 2020

1 reference

Interferon-α Treatment for Growing Teratoma Syndrome of the Testis

31 March 2020

1 reference

Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501): practical experiences in problem-patients with actinic keratoses and basal cell carcinomas

31 March 2020

1 reference

High efficiency cell-specific targeting of cytokine activity

31 March 2020

1 reference

Classification of current anticancer immunotherapies

31 March 2020

1 reference

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

31 March 2020

1 reference

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

31 March 2020

1 reference

Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities

31 March 2020

1 reference

hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function

31 March 2020

1 reference

Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo

31 March 2020

1 reference

Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models

31 March 2020

1 reference

Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression

31 March 2020

1 reference

Type I IFN gene delivery suppresses regulatory T cells within tumors

31 March 2020

1 reference

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity

31 March 2020

1 reference

RNA recognition and signal transduction by RIG-I-like receptors

31 March 2020

1 reference

5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

31 March 2020

1 reference

Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGFβ and activating RIG-I.

31 March 2020

1 reference

CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity.

31 March 2020

1 reference

Trial Watch: Toll-like receptor agonists in oncological indications

31 March 2020

1 reference

Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line

31 March 2020

1 reference

Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells

31 March 2020

1 reference

The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse

31 March 2020

1 reference

The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line

31 March 2020

1 reference

Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature.

31 March 2020

1 reference

Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses

31 March 2020

1 reference

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

31 March 2020

1 reference

Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses

31 March 2020

1 reference

Plasmacytoid Dendritic Cells: Recent Progress and Open Questions

31 March 2020

1 reference

Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons

31 March 2020

1 reference

CD141 dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice

31 March 2020

1 reference

IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells.

31 March 2020

1 reference

Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation

31 March 2020

1 reference

F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells

31 March 2020

1 reference

Autophagy and cellular immune responses

31 March 2020

1 reference

Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA.

31 March 2020

1 reference

Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production

31 March 2020

1 reference

Mitochondria: master regulators of danger signalling

31 March 2020

1 reference

Phosphoinositide 3-kinase regulates a subset of interferon-alpha-stimulated genes

31 March 2020

1 reference

IFN- Skews Monocytes into CD56 -Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo

31 March 2020

1 reference

The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment

31 March 2020

1 reference

Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.

31 March 2020

1 reference

Type I interferon protects antiviral CD8 T cells from NK cell cytotoxicity.

31 March 2020

1 reference

Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1β production in human macrophages

31 March 2020

1 reference

Interferon-α suppresses cAMP to disarm human regulatory T cells.

31 March 2020

1 reference

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

31 March 2020

1 reference

Alpha interferon for induction of remission in hairy-cell leukemia

31 March 2020

1 reference

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

31 March 2020

1 reference

Interferon therapy in myelomatosis

31 March 2020

1 reference

Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon

31 March 2020

1 reference

Interferons in the treatment of solid tumors

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26027717

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Major depression during interferon-alpha treatment: vulnerability and prevention

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26027717

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

[Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26027717

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRI3845

1 reference

Dimensions Publication ID

3 September 2017

1049369736

0 references

1 reference